Sources & References
Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
2023 • PMID: 37366315 • DOI: 10.1056/NEJMoa2301972
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
2023 • PMID: 37385280 • DOI: 10.1016/S0140-6736(23)01053-X
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
2026
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
2025 • PMID: 40609566 • DOI: 10.1016/S2213-8587(25)00092-0
